Please assess the completion status of the following clinical trial:

Trial Title: Study Evaluating Sphenopalatine Ganglion Block (SPGB) for Treatment of Postdural Puncture Headache (PDPH)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: EARLY_PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria~* Active postdural puncture headache within 7 days after neuraxial analgesia/anesthesia~* Age ≥ 18 years.~* ASA physical status ≤ 3~Exclusion Criteria~* Known coagulopathy~* Known nasal septal deviation or abnormalities~* Medical conditions contraindicated to bupivacaine or the nasal applicator (according to the product labeling)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Acitve (Type: ACTIVE_COMPARATOR): This group will receive 0.3 ml of 0.5% bupivacaine per nare, applied with the Tx360®
- Placebo (Type: PLACEBO_COMPARATOR): This group will receive 0.3 ml of normal saline per nare, applied with the Tx360®

Based on this trial design, predict the completion outcome and termination type (if applicable).